Aventix Raises €1.2M Pre-Seed Led by Voima Ventures for Microplate Analytics

Aventix Closes €1.2M Pre-Seed Round

Aventix, a Swedish bioanalytics technology company, has raised €1.2 million in Pre-Seed funding. The round was led by Voima Ventures, with participation from Kost Capital. The funding was announced on September 30, 2026.

What Aventix Does

Aventix builds sensor-based tools designed to make laboratory data collection faster, more reliable and easier to verify. The company operates at the intersection of optical sensing, purpose-built software and AI models.

Its first product, Scarlett 01, delivers non-contact volume analytics for microplates. According to the company, Scarlett 01 can process a full 96-well plate in about 30 seconds — a workflow that combines optical sensing hardware with dedicated software and AI models.

The company serves pharmaceutical, chemical, agricultural and cosmetic R&D labs, and is rolling out across North America and Europe.

Founding Team

Aventix was founded by serial entrepreneurs Erik Gatenholm and Hector Martinez. The pair previously co-founded CELLINK, which later became BICO Group. That background gives the company a founder profile with prior experience scaling laboratory technology into commercial markets.

The Round at a Glance

• Company: Aventix
• Round type: Pre-Seed
• Amount: €1.2 million
• Announced: September 30, 2026
• Lead investor: Voima Ventures
• Additional investors: Kost Capital
• Stage: Pre-Seed

Why This Matters for the Lab Analytics Market

Microplate-based workflows are foundational to a wide range of R&D environments, from drug discovery to agricultural and cosmetic formulation. Volume analytics is a recurring step in those workflows, and the value proposition Aventix is pursuing centers on speed, reliability and verifiability of the data collected.

The company's positioning — non-contact sensing plus software plus AI models — places it in the broader laboratory automation and analytics category, where instrument vendors and software providers increasingly compete on integration and throughput.

Acquisition Angle

For acquirers in life-science tools, laboratory automation and analytical instrumentation, Aventix represents an early-stage asset with:

• A defined first product (Scarlett 01) targeting a specific, high-frequency lab workflow
• A founding team with a prior exit-scale outcome in CELLINK/BICO Group
• A customer base spanning pharmaceutical, chemical, agricultural and cosmetic R&D
• A geographic rollout across North America and Europe

At Pre-Seed, the company is early in its commercial trajectory. Strategic buyers and investors tracking microplate analytics, non-contact sensing and AI-assisted lab data workflows may view the round as an entry point into a team with prior category experience.

What to Watch

Key questions for the next phase include commercial traction for Scarlett 01, expansion of the product line beyond microplate volume analytics, and the pace of the North America and Europe rollout. The involvement of Voima Ventures as lead and Kost Capital as an additional investor provides the initial capital base for that execution.

No further terms, valuation or use-of-proceeds details were disclosed in the funding announcement.